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Objective. To asses a cohort of 105 consecutive patients with angiotensin converting enzyme-inhibitor induced angioedema with
regard to demographics, risk factors, family history of angioedema, hospitalization, airway management, outcome, and use of
diagnostic codes used for the condition. Study Design. Cohort study.Methods. This was a retrospective cohort study of 105 patients
with angiotensin converting enzyme-inhibitor induced angioedema in the period 1995–2014. Results. The cohort consisted of 67
females and 38 males (F :M ratio 1.8), with a mean age of 63 [range 26–86] years. Female gender was associated with a significantly
higher risk of angiotensin converting enzyme-inhibitor induced angioedema. 6.7% had a positive family history of angioedema.
Diabetes seemed to be a protective factor with regard to angioedema. 95% experienced angioedema of the head and neck. 4.7%
needed intubation or tracheostomy. 74 admissions took place during the study period with a total of 143 days spent in the hospital.
The diagnosis codes most often used for this condition were “DT783 Quincke’s oedema” and “DT78.4 Allergy unspecified”.
Complement C1 inhibitor was normal in all tested patients. Conclusion. Female gender predisposes to angiotensin converting
enzyme-inhibitor induced angioedema, whereas diabetes seems to be a protective factor.
1. Introduction
Angioedema is a transient nonpitting swelling of the dermis
and subcutis or submucosa which occurs in a variety of
diseases. Asphyxiation is a risk when angioedema localizes
in the oral cavity, pharynx, or larynx [1]. When the physi-
cian encounters patients with severe acute and/or recurrent
angioedema, both treatment and assessment might be a
challenge [2]. Angioedema can occur as an adverse effect to
several medications, but one drug class is overrepresented,
namely, angiotensin converting enzyme-inhibitors (ACEi)
[1, 3]. Over the past twenty years, it has become evident
that ACEi induced angioedema is frequently misdiagnosed
as allergic reactions resulting in the use of noneffective antial-
lergicmedications and failure to withdraw the offending drug
[2, 4]. In a few cases, a genetic predisposition toACEi induced
angioedema has been found [5–7]. Seemingly, ACEi induced
angioedema is related to polygenetic and demographic as
well as environmental factors such as age, race, gender,
comorbidity, and smoking, but most available studies are
describing heterogeneous and relatively small sample sizes
[1, 8]. Also standardized clinical assessments of patients
regarding other causes of angioedema are often lacking.
This retrospective study of the clinical characteristics
of patients suffering from ACEi induced angioedema was
carried out at a Danish Department of Dermatology and
Allergy Centre. Patients referred to the department had a
history of severe and/or recurrent angioedema of unknown
cause and were thoroughly assessed using a systematic
angioedema guideline. The main objectives of the study were
Hindawi
International Journal of Otolaryngology
Volume 2017, Article ID 1476402, 7 pages
https://doi.org/10.1155/2017/1476402
2 International Journal of Otolaryngology
to describe a large presumed Caucasian cohort with ACEi
induced angioedema. Furthermore, previously identified risk
factors would be assessed to see whether we could validate
the findings. Also, the study served as a quality study for our
department, which holds the regional service for angioedema
assessment.
2. Materials and Methods
A retrospective study of patients diagnosed with ACEi
induced angioedema in the period 1995–2014 was performed
at a single department of dermatology and allergology,
Odense University Hospital, which serves a population of 1.2
million people. Patient data was entered into a database in
order to ensure correct and reliable data collection. Stata
version 14 (StataCorp. 2015, Stata Statistical Software: Release
14. College Station, TX: StataCorp LP.) was used as database
system and for analysis. For statistical analysis, differences
of proportion test together with multivariate logistic regres-
sion analyses were used. 𝑝 values ≤ 0.05 were considered
statistically significant. Relative risk calculation was based
on the study population and data (ACEi treated males and
females) from the Danish registry on sale of pharmaceuticals
1996–2014 [9]. As there was no control group, statistics was
performed comparing groups of patients with each other (i.e.,
males and females, smokers and nonsmokers, and patients
with and without hypertension).
2.1. Ethics. This study was approved by the Danish Data Pro-
tectionAgency (jr. number 14/35206) and theDanishNational
Board of Health (jr. number 3-3013-805/1/) as appropriate.
3. Results
Of 734 consecutive patients assessed due to angioedema,
105 patients were found to have ACEi induced angioedema
and were included in the study (Table 1). There was a
predominance of females and the mean age was 63 years
[range 26–86 years].The age distribution is shown in Figure 1.
The female overrepresentation reached statistical significance
(𝑝 = 0.006; 95% confidence interval (CI) 0.09–0.47). Using
MedStat.dk, which is a tool to extract data on prescribed
pharmaceuticals in Denmark, we found that 23%more males
than females receive an ACEi in the study period [9]. The
relative risk of angioedema due to ACEi in females versus
males was found to be 1.4 [9].
Patients were most often referred by their general prac-
titioner; 9.5% of them were referred twice due to recurrent
angioedema episodes afterwithdrawal of ACEi.Most patients
had experienced more than one angioedema episode prior
to referral (Table 1). Relatively few patients needed airway
management (Table 2).
More than half the patients had been admitted to hospital
due to angioedema at least once with a total of 74 admissions
and 143 patient-days spent in hospital (Table 3). Furthermore,
48 of 100 patients had been assessed at an EmergencyDepart-
ment due to angioedema, while the history of Emergency
Department visits was unknown for five patients (Table 3).
A variety of diagnostic codes (International Classifi-
cation of Diseases version 10) were used when admitting
Table 1: Basic data.
Parameter
Patients, 𝑛 105
Male : female 38 : 67
Caucasians 104 (99%)
Age, mean, years 63 [range 26–86](SD 12.42)
Referred > 1 due to recurrent
angioedema, 𝑛 (%) 10 (9.5%)
Referring medical specialty
(i) General practitioner 47
(ii) Internal medicine 28
(iii) Emergency department 11
(iv) Otorhinolaryngology 10
(v) Referred from 2 specialties 6
(vi) Dermatology 1
(vii) Allergy centre 1
(viii) Unknown 1
Follow-up, patient-months
(mean) 700 (6.7)
History of drug rash
No 72.3%
Yes 27.6%
History of allergic disease
No 76.1%
Yes 22.0%
Unknown 1.9%
Smoking
No 38.0%
Yes 24.8%
Unknown 37.1%
Family history of angioedema
No 75.2%
Yes 6.7%
Unknown 18.0%
Number of angioedema episodes
prior to referral
1 20.0%
2 7.6%
3–5 17.1%
6–10 9.5%
11–20 4.8%
21–50 1.9%
>50 8.6%
Unknown 30.5%
angioedema patients with “DT 78.3 Quincke’s oedema” and
“DT 78.4 Allergy without specification” used in 75–90% of
cases in both the Emergency Department and other in-
patient departments (Table 3).
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Table 2: Descriptive angioedema incident data. Some patients had experienced angioedema in more than one location; thus, the numbers
does not add up to 100.
Parameter
Localization of angioedema, 𝑛, (%)
(i) Head and neck 100 (95.2%)
(ii) Peripheral 14 (13.3%)
(iii) Abdominal 3 (2.9%)
Concomitant rash, 𝑛, (%) 19 (18%)
Treatment of acute attacks, 𝑛, (%)
Antihistamines 96 (91.4%) Efficacy reported by 62.5%
Corticosteroids 79 (75.2%) Efficacy reported by 63.3%
Adrenaline 20 (19.0%) Efficacy reported by 15.0%
Icatibant 3 (2.9%) Efficacy reported by 66.7%
Tranexamic acid 1 (<1%) Efficacy reported by 0%
Beta-2 agonists 1 (<1%) Unknown effect
Montelukast 2 (1.9%) Unknown effect
Azathioprine 1 (<1%) Unknown effect
Airway management
Intubation 4 patients 3.8%
Tracheostomy 1 patient 0.9%
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Figure 1: Age distribution of the cohort.
As a group, patients with ACEi induced angioedema had
many concomitant diseases, predominantly associated with
smoking, alcohol use, obesity, and allergic diseases. Using
difference of proportion tests, the incidence of hypertension
was not surprisingly overrepresented (𝑝 < 0.0001; 95% CI
0.66–1.04). Diabetes was shown to be a significant protective
factor (𝑝 < 0.005; 95% CI 0.37–0.75) (Table 4). The risk
of angioedema was not found to correlate with smoking
(Table 1)
In a minor fraction of patients, C-reactive protein or
tryptase was elevated (Table 5). None of the patients with
recurrent angioedema after ACEi withdrawal had a positive
histamine-release (HR) test or elevated tryptase, but three
had concomitant rash. All tested patients had normal com-
plement C1 inhibitor levels and function.
Obvious parameters associated with admission to a hos-
pital were intubation and tracheostomy. Inmultivariate logis-
tic regression analysis, angioedema located in the head and
neck region was nonsignificantly associated with admission
(odds ratio (OR) 5.9 (𝑝 = 0.15, 95% CI 0.53–98.49)), while
angioedema in peripheral sites was significantly associated
with not being admitted (OR 0.15 (𝑝 = 0.05 95% CI, 0.01–
0.95) (Table 6)).
4. Discussion
Our study confirmed female gender as a risk factor of ACEi
induced angioedema (𝑝 = 0.006), which previously has
been disputed [10]. A possible bias in our study could be
more women than men being treated with an ACEi. To
assess this, we used MedStat.dk, which is a tool to extract
data on prescribed pharmaceuticals in Denmark [9]. In
fact, the prescription rate of ACEi for men was 23% higher
than that for women, even though there are more women
than men in this age group (typically > 45 years of age).
This further consolidates female gender as a risk factor. In
hereditary angioedema, symptoms are oftenworse inwomen,
presumably due to an interaction with estrogen, but this has
never been studied in ACEi induced angioedema [11].
Smoking has been identified as a risk factor in earlier
studies, but no association was found in this study [12, 13].
Diabetes seems to be a protective factor, whichwas confirmed
by our study (21% with versus 79% without diabetes, 𝑝 <
0.005) [14]. The negative correlation between diabetes and
ACEi angioedema has not been fully understood. However,
it seems that poor blood glucose control and high levels of
HbA1c might increase the level of Dipeptidyl-Peptidase IV
[15]. This enzyme is one of the main metabolizers of the
vasoactive molecules bradykinin and substance P, which are
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Table 3: Data regarding hospital admissions and Emergency
Department visits. Data was unknown regarding admissions in two
patients. Three patients were admitted, but the number of admis-
sions was unknown. Thus, they count as one admission each, even
though some might have been admitted more than once; therefore,
the number of hospitalizations is an approximatedminimum. In five
patients, the duration of admission was unknown. Diagnostic codes
are from the International Classification of Diseases, Tenth Edition
(ICD-10).
Hospitalization data
Patients assessed at Emergency Department 48
Patients admitted to a hospital 55
Number of admissions, total 74
1 39 patients
2 7 patients
3 2 patients
4 4 patients
Unknown number 3 patients
Days of admission, total 143
Days of admission, mean, [range] 2.9 [1–35]
Department of initial admission
(i) Internal Medicine 40
(ii) Otorhinolaryngology 19
(iii) Emergency Department 6
(iv) Intensive Care Unit 2
(v) Dermatology and Allergy 2
(vi) Unknown 5
Diagnostics codes in Emergency Department
(i) DT78.3 Quincke’s edema 56.3%
(ii) DT78.4 Allergy unspecified 33.3%
(iii) DT88.6 Anaphylactic shock 2.0%
(iv) Miscellaneous 8.4%
Diagnostic codes in other departments
DT78.3 Quincke’s edema 59.6%
DT78.4 Allergy unspecified 15.9%
DT88.6 Anaphylactic shock 2.1%
Miscellaneous 18.1%
Unknown 4.3%
suspected to be the primarymediators for ACEi angioedema.
In addition, low levels of Dipeptidyl-Peptidase IV have
previously been correlated with ACEi angioedema [8].
Allergic rhinitis, asthma, and atopic dermatitis were
not significantly associated with ACEi angioedema in this
study. However, a few patients had positive HR test (2.9%)
and/or elevated tryptase (5.7%). Those patients might have
an underlyingmast cell driven condition, which raised their a
priori risk of angioedema during ACEi treatment. It has been
proposed that an initial histamine-release reaction can set
off bradykinin-mediated angioedema attacks, although this
needs clarification [16, 17].
6.7% had a positive family history of angioedema, but
none of them had complement C1 inhibitor deficiency.
Angioedema is relatively prevalent in the general population,
and some families might have a genetic predisposition that
Table 4: Concomitant disease. Numbers do not add up to 100%, as
some patients had more than one concomitant disease.
Disease Frequency, 𝑛, (%)
Hypertension 97 (92.4%)
Diabetes 23 (21.9%),
Other ischemic heart disease 16 (15.2%)
Rheumatic disease 14 (13.3%)
Heart failure 13 (12.4%)
Hypercholesterolemia 13 (12.4%)
Allergic rhinitis 10 (9.5%)
Asthma 9 (8.6%)
COPD 6 (5.7%)
Atopic dermatitis 6 (5.7%)
Psychiatric disease 5 (4.8%)
Osteoporosis 4 (3.8%)
History of stroke 4 (3.8%)
Thyroid disease 3 (2.9%)
Cancer 3 (2.9%)
is not yet understood [18, 19]. As expected, all tested patients
had normal levels of complement C1 inhibitor.
Every fifth patient in our cohort had a description of
rash/urticaria in their medical records. However, we suspect
that both patients and physicians have trouble distinguish-
ing between urticaria and angioedema, as some describe
angioedema as “giant hives.” Usually, ACEi angioedema is
not associated with urticaria.
It has been proposed that a known idiopathic angioedema
could increase the risk of attacks, when treated with ACEi,
but as no data were available on idiopathic angioedema prior
to ACEi treatment, we were not able to study this further
[20]. African descent is another known risk factor both
for angioedema due to ACEi and for the need for airway
management, signifying a severe angioedema [1, 21]. Our
cohort did not include any patients of African descent, so we
were not able to verify this previous finding.
The number of patients in need of acute airway manage-
ment was a little higher than in a previous American study
by Tai et al.: intubation 3.8% versus 3.3% and tracheostomy
0.9% versus 0.3% [1]. However, an earlier study from 2007
by Grant et al. displays a larger proportion of intubations,
namely, 10% [22]. The demographics in the United States of
America and Denmark differ with regard to race, as more
people in the US have African ancestry; this might have
significance when comparing studies [22]. In the literature,
an algorithmhas beenproposed for assessment and treatment
of angioedema in the acute phase [23]. This is an important
notion, since the hypopharynx and larynx are not visualized
by a routine inspection of the oral cavity. In patients not
assessed by an otorhinolaryngologist, close attention should
be paid to clinical clues to a potential hypopharynx or larynx
swelling: inability to swallow foods/liquids, changed voice,
hoarseness, drooling, patient stating to feel a “lump in the
throat,” and stridor. Angioedema due to an ACEi tends to
have a more severe clinical presentation than most other
International Journal of Otolaryngology 5
Table 5: Laboratory tests performed.
Laboratory tests Result % of cohort
Complement C1-inhibitor tests Normal 72.4%
Not tested 27.6%
HR test chronic urticaria
Negative 55.2%
Not tested 40.0%
Positive 2.9%
Data missing 1.9%
Increased C-reactive protein Range 7–126 (normal < 6mg/L) 14.3%
Leukocytosis More than 8.8 × 109/L 15.2%
Tryptase More than 12 ng/mL 5.7%
Table 6: Multivariate logistic regression analysis. Association between different factors and the need for admission. ∗Significant result,
peripheral angioedema less likely to cause the patient to be admitted. 1High odds ratios for admission.
Odds ratio Standard error 𝑧 𝑝 > 𝑧 95% confidence interval
Male versus female sex 0.74 0.40 −0.55 0.58 0.25–2.15
Urticaria 0.42 0.28 −1.33 0.19 0.11–1.52
Head and neck angioedema 6.931 9.05 1.48 0.14 0.53–98.49
Peripheral angioedema 0.14 0.14 −2.00 0.05∗ 0.01–0.95
Smoking 2.021 1.29 1.10 0.27 0.57–7.06
Rash 1.05 0.58 0.10 0.92 0.35–3.11
Diabetes 1.78 1.14 0.91 0.37 0.50–6.23
Hypertension 0.72 0.68 −0.35 0.73 0.11–4.53
Ischemic heart disease 1.16 0.45 0.39 0.70 0.54–2.48
Heart failure 1.23 0.57 0.44 0.66 0.49–3.06
Atopic dermatitis 0.66 0.68 −0.40 0.69 0.08–5.01
Allergic rhinitis 2.301 2.15 0.89 0.37 0.37–14.39
Asthma 0.78 0.45 −0.43 0.67 0.25–2.42
forms of angioedema, and deaths due to airway obstruction
have been described [24].
The recurrence of angioedema in patients on continued
ACEi treatment is 187 per 1000 patient-years, butwith a rather
long latency—on average 11 months to the next attack [25].
All patients in the present study had their ACEi discontinued
after assessment at our department. During the follow-up
period of 700 patient-months, 10 of 105 (9.5%) patients expe-
rienced recurrent angioedema after the withdrawal of ACEi.
A national registry based study found a similar recurrence
rate of nine percent, while two retrospective clinical studies
found higher recurrence rates [25–27]. A limitation of our
study is that patients with mild or infrequent angioedema
episodes might not have been rereferred to our department
and thus not registered with recurrence. Mahmoudpour et al.
found that 32–53% of patients with a first-time angioedema
attack discontinued ACEi in 2007–2013 (increasing over
the time period) [26]. Medical guidelines advise that ACEi
should be replaced with an angiotensin 2-receptor blocker
(ARB) if adverse drugs reactions occur [28]. In a recent study
of ACEi adverse reactions, 43% of angioedema patients were
switched to an ARB, 14% switched to “other hypertensive
drugs,” and 14% stopped without replacement therapy; the
remainder stayed on ACEi [29]. Angioedema recurrence
rates were not statistically different between patients that
switched to various alternative hypertensive drugs (ARB 34%,
calcium antagonists 28% and “other” 29%, 𝑡-test and Mann–
Whitney U test 𝑝 > 0.05) [30]. One hypothesis is that ACEi
treatment can be the trigger of a latent predisposition to
(idiopathic) angioedema. However, genetic factors are also
involved in ACEi angioedema, and in one patient multiple
enzyme deficiencies were seen [5, 31].
The efficacy of antihistamines (62.5%) and/or corticos-
teroids (63.3%) reported by patients and physicians are most
likely explained by a high spontaneous remission rate of
ACEi angioedema, as the bradykinin pathway is not affected
by classical antiallergic medication. It is noteworthy that we
find the reported efficacy of antiallergic treatments is the
same as for the newer drug icatibant, which is a selective
bradykinin-2 antagonist. The low number of treated patients
does not allow for any conclusions, but a previous study
would suggest icatibant to be more effective than antiallergic
treatment [32]. One of the important focus areas of medical
science—personalized medicine—is aiming to find genetic
and clinical factors that predict patients at risk of ACEi
induced angioedema, and to these patients another drug
should be prescribed. Until such tests and prediction models
are available, physicians and patients rely on a thorough
assessment of patients with angioedema in order to distin-
guish between ACEi induced and other types of angioedema.
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5. Conclusion
In conclusion, this study validates older age and female sex
as risk factors of ACEi angioedema, while smoking habits
and allergies were not associated. An important finding was
that patients with diabetes seem to be protected against
ACEi angioedema occurrence; this fact should be explored
in upcoming studies. Patients with angioedema of the head
and neck were admitted to hospital to a high extent due to the
risk of airway obstruction, whereas patients with peripheral
angioedema were less likely to be admitted.
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